A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3)

Phase 4

Completed

• Conditions: Hypertension
• Interventions: Drug: Losartan 50 mg / HCTZ 12.5 mg

• Registration Number: NCT01431508
• Lead Sponsor: Organon and Co

Brief Summary

This study is being conducted to evaluate the safety and antihypertensive efficacy of MK-0954A (Losartan 50 mg / Hydrochlorothiazide (HCTZ) 12.5 mg) in participants with mild to moderate essential hypertension.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-08-01
• Primary Completion: 2009-06-01
• Study Completion: 2009-06-01
• Study First Submitted: 2011-09-07
• Study First Submitted QC: 2011-09-08
• Study First Posted: 2011-09-09
• Results First Submitted: 2011-10-13
• Results First Submitted QC: 2011-10-13
• Results First Posted: 2011-11-22
• Status Verified: 2022-02
• Last Update Submitted: 2024-05-08
• Last Update Posted: 2024-05-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Losartan 50 mg / HCTZ 12.5 mg	Losartan 50 mg / HCTZ 12.5 mg	Participants with mild to moderate essential hypertension who will receive Losartan 50 mg / HCTZ 12.5 mg once-a-day for 12 weeks.

Primary Outcome Measures

Name	Time	Method
Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12	At Baseline and Week 12	Participants with SiDBP of 95-115 mmHg at the end of Baseline had SiDBP measured after 12 weeks of treatment.